Specific Biologics Strengthens Leadership with Dr. Richard Glickman's Appointment to Board

Specific Biologics Enhances Leadership with Dr. Richard Glickman

TORONTO, December 16, 2025 – Specific Biologics Inc., a leader in precision in vivo genome editing, has announced the addition of Dr. Richard Glickman to its Board of Directors. This strategic appointment is expected to drive the company forward as it continues to innovate with its unique Dualase® genome editing technology.

Dr. Glickman brings over 30 years of extensive experience in the biotechnology sector, marked by a history of successful drug development and an impressive track record in corporate strategy and commercialization. His entrepreneurial spirit has led him to co-found several biopharmaceutical firms, such as StressGen Biotechnologies and Aspreva Pharmaceuticals, showcasing his dedication to advancing medical science.

During his tenure in the industry, Dr. Glickman has successfully navigated multiple companies from their nascent stages through clinical trials to commercial success. Notably, he spearheaded the Aspreva Pharmaceuticals journey culminating in its $915 million acquisition. His governance experience spans across numerous public and private biotechnology firms where he held leadership roles, including chairing Aurinia Pharmaceuticals and ESSA Pharma.

Specific Biologics is at a critical junction in its development of Dualase®, which serves as a versatile genome editing platform aimed at addressing unmet medical needs in genetic diseases. Dr. Paul J. Hastings, Chair of the Board, expressed enthusiasm regarding Dr. Glickman’s appointment, stating, "His wealth of experience in building biotech companies and securing strategic partnerships will be vital as we work to bring our innovative technologies to those who need them most."

In his remarks, Dr. Glickman highlighted his excitement about the potential of Dualase® to provide innovations in treating diseases like amyotrophic lateral sclerosis (ALS), emphasizing the urgent need for groundbreaking therapies in this domain. "Specific Biologics stands at the cutting edge of in vivo genome editing. The company’s differentiated approach has the capability to robustly treat various genetic diseases, and I am eager to collaborate closely with the leadership team to propel our initiatives forward," Dr. Glickman stated.

As Dr. Glickman joins the Board, Specific Biologics also acknowledges the contributions of Frédéric Lemaître Auger, who will be stepping down from his position on the Board. The company expresses gratitude for his invaluable guidance and support since its inception. CEO Brent Stead remarked on Dr. Lemaître Auger's vital role in shaping the firm’s strategic direction as it gears up for its expansion into the clinic.

Specific Biologics continues to strengthen its leadership team, aiming for a world-class governance structure that aims to push the boundaries of genome editing therapies. The company's proud track record of in vivo proof-of-concept, along with a robust intellectual property portfolio, underpin its commitment to driving forward with cutting-edge medical solutions that address pressing health challenges.

For further information about Specific Biologics and its innovative approach to genomic therapy, visit Specific Biologics or connect on LinkedIn.